Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far
Will Boost From ASCO, Aduhelm Improve Investor Sentiment?
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
